Adlai Nortye Biopharma Co., Ltd., a biopharmaceutical company, has entered into a global licensing agreement with Eisai Co., Ltd., a global pharmaceutical company with a focus on serving patients with unmet medical needs. Under the terms of the agreement, Adlai Nortye will have exclusive worldwide research, development, manufacture, and commercialization rights to E7046, excluding Japan and part…